Jakavi (Ruxolitinib) is a targeted therapy used to treat certain blood and bone marrow disorders. It works by targeting specific signaling pathways involved in abnormal blood cell production and inflammation associated with these conditions.
What is Jakavi (Ruxolitinib)?
Jakavi belongs to a class of medications known as Janus Kinase (JAK) Inhibitors.
In some blood disorders, JAK signaling becomes overactive, leading to abnormal blood cell production and disease-related symptoms. Jakavi works by:
- Inhibiting JAK signaling pathways
- Reducing disease-related symptoms
- Helping improve disease control
In simple terms:
It targets the signals that contribute to the progression of certain blood disorders.
Indications
Jakavi (Ruxolitinib) is used in:
- Myelofibrosis
- Polycythemia Vera in selected cases
- Other conditions as determined by the treating physician
Dosage and Administration
- Dose varies depending on the condition and laboratory results
- Taken orally
- Usually administered twice daily
- Should be taken exactly as prescribed
- Dose adjustments may be required based on patient response
Common Side Effects
May include:
- Low blood cell counts
- Dizziness or headache
- Fatigue
- Increased risk of infections
- Mild bruising or bleeding
Regular monitoring is important during treatment.
Monitoring During Treatment
Patients on Jakavi (Ruxolitinib) require:
- Regular complete blood count (CBC) monitoring
- Assessment of treatment response
- Monitoring for signs of infection or bleeding
- Evaluation of overall health status
Availability & How to Access Treatment
Jakavi (Ruxolitinib) is available through Macrocare’s approved partners.
You can now request and access the medication easily through us.
WhatsApp contact for medication requests:
Click here
Jakavi (Ruxolitinib) Jakavi (Ruxolitinib) 15 mg is a targeted therapy for bone marrow disorders such as myelofibrosis, helping reduce symptoms and improve disease control.
Medical Disclaimer:
This content is for educational purposes only and does not replace professional medical advice. Treatment decisions should always be made by a qualified physician.
